Overview

Topical SGX302 for Mild-to-Moderate Psoriasis

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

To evaluate SGX302 (topical hypericin ointment) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.

Phase:

Phase 2

Details

Lead Sponsor:

Soligenix

Treatments:

Hypericin